Nivolumab-induced interstitial lung disease in a patient with gastric cancer.

We herein report a case of nivolumab-induced interstitial lung disease in a patient with gastric cancer. Nivolumab is a fully human IgG4 monoclonal antibody inhibitor of programmed death-1. A 69-year-old woman with metastatic gastric cancer being treated with nivolumab as fifth-line therapy developed interstitial pneumonia 27 months after starting treatment with nivolumab.

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis.

Background: Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Ramucirumab either alone or in combination with paclitaxel (PTX) has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the serious adverse events associated with ramucirumab is gastrointestinal (GI) perforation.

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.

Recent advances in positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET) have facilitated not only the diagnosis and staging of lung cancer, but also the prediction of treatment outcome. The present study was designed to assess the usefulness of early FDG-PET examination for predicting subsequent tumor size reduction in response to molecular targeted agents in metastatic non-small cell lung cancer (NSCLC) with sensitive gene anomalies. I.

Effect of Exercise Training on Red Blood Cell Distribution Width as a Marker of Impaired Exercise Tolerance in Patients With Coronary Artery Disease.

Red blood cell distribution width (RDW) can predict mortality in cardiovascular disease. However, the underlying mechanisms of the beneficial prognostic marker remain unknown. The purpose of this study was to investigate whether the RDW is related to impaired exercise tolerance and exercise training (ET) effect on RDW in patients with coronary artery disease (CAD).

Intestinal carriage and excretion of Campylobacter jejuni in chickens exposed at different ages.

Campylobacter jejuni is usually recovered from chickens in commercial broiler farms after 2 to 3 weeks of age. This study was conducted to clarify whether fecal excretion is associated with the age of exposure to this bacterium. Day-of-hatch broiler chickens were separated from a flock in a local commercial farm, kept in isolation rooms, and esophageally inoculated with C.